“I think cell therapy is going to continue to be a very, very important treatment modality for cancer, and we would like to see the Tampa Bay area become the cell therapy capital of the universe,” Hwu, the new president and CEO of H. Lee Moffitt Cancer Center, said to The Cancer Letter.
The National Cancer Institute approved the following clinical research studies last month.
FDA has granted accelerated approval to Danyelza (naxitamab-gqgk) 40mg/10ml in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Gavreto (pralsetinib) received FDA approval for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
FDA has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for positron emission tomography imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer.
The European Commission has approved Opdivo (nivolumab) for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.
The European Medicines Agency has validated for review the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer harboring mesenchymal-epithelial transition factor gene exon 14 skipping alterations.
Israel Cancer Research Fund has announced 69 cancer research grants, valued at $4.7 million, will be supported for the 2020-2021 funding year.
University of Virginia Cancer Center researchers have identified a gene responsible for the spread of triple-negative breast cancer to other parts of the body, and developed a potential way to stop it.
City of Hope has initiated a phase I clinical trial that will test one of its investigational SARS-CoV-2 vaccines in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
